Q-omics provides the consensus-scored FOXD3 profile across patient tissues and cancer cell-line models. FOXD3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FOXD3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FOXD3 RNA expression shows 14,509 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where FOXD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXD3 survival associations across molecular data types. FOXD3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXD3 RNA expression–survival associations across cancer types. High FOXD3 expression shows unfavorable associations in KIRP, ACC, UCEC, KICH, KIRC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FOXD3 RNA expression.
This table summarizes FOXD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FOXD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXD3 shows lower tumor expression in COAD, THCA, BLCA and KIRC and higher tumor expression in HNSC and LUSC. The COAD box plot shows higher FOXD3 RNA expression in normal versus tumor tissue (log2 FC = −1.099, t-test p < 0.001).
This table shows molecular features associated with FOXD3 in patient tissues and cancer cell lines. In patient samples, FOXD3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
